JP2018526987A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018526987A5 JP2018526987A5 JP2018504942A JP2018504942A JP2018526987A5 JP 2018526987 A5 JP2018526987 A5 JP 2018526987A5 JP 2018504942 A JP2018504942 A JP 2018504942A JP 2018504942 A JP2018504942 A JP 2018504942A JP 2018526987 A5 JP2018526987 A5 JP 2018526987A5
- Authority
- JP
- Japan
- Prior art keywords
- amino acid
- seq
- polypeptide
- acid residue
- acid residues
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 125000000539 amino acid group Chemical group 0.000 claims 28
- 229920001184 polypeptide Polymers 0.000 claims 15
- 102000004196 processed proteins & peptides Human genes 0.000 claims 15
- 108090000765 processed proteins & peptides Proteins 0.000 claims 15
- 102000040430 polynucleotide Human genes 0.000 claims 8
- 108091033319 polynucleotide Proteins 0.000 claims 8
- 239000002157 polynucleotide Substances 0.000 claims 8
- 150000001413 amino acids Chemical class 0.000 claims 6
- 102400001047 Endostatin Human genes 0.000 claims 4
- 108010079505 Endostatins Proteins 0.000 claims 4
- 125000003275 alpha amino acid group Chemical group 0.000 claims 4
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 2
- 239000004472 Lysine Substances 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 239000002246 antineoplastic agent Substances 0.000 claims 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 2
- 229940127089 cytotoxic agent Drugs 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 208000006168 Ewing Sarcoma Diseases 0.000 claims 1
- 206010029260 Neuroblastoma Diseases 0.000 claims 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 1
- 201000000582 Retinoblastoma Diseases 0.000 claims 1
- 230000021736 acetylation Effects 0.000 claims 1
- 238000006640 acetylation reaction Methods 0.000 claims 1
- 208000009956 adenocarcinoma Diseases 0.000 claims 1
- 230000009435 amidation Effects 0.000 claims 1
- 238000007112 amidation reaction Methods 0.000 claims 1
- 230000006242 butyrylation Effects 0.000 claims 1
- 238000010514 butyrylation reaction Methods 0.000 claims 1
- 210000004899 c-terminal region Anatomy 0.000 claims 1
- 229960004562 carboplatin Drugs 0.000 claims 1
- 190000008236 carboplatin Chemical compound 0.000 claims 1
- 235000012000 cholesterol Nutrition 0.000 claims 1
- 229960004316 cisplatin Drugs 0.000 claims 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 230000000295 complement effect Effects 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000002708 enhancing effect Effects 0.000 claims 1
- 239000013604 expression vector Substances 0.000 claims 1
- 230000022244 formylation Effects 0.000 claims 1
- 238000006170 formylation reaction Methods 0.000 claims 1
- 239000012634 fragment Substances 0.000 claims 1
- 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 201000005243 lung squamous cell carcinoma Diseases 0.000 claims 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 1
- 230000004048 modification Effects 0.000 claims 1
- 238000012986 modification Methods 0.000 claims 1
- 201000008968 osteosarcoma Diseases 0.000 claims 1
- 229960001756 oxaliplatin Drugs 0.000 claims 1
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 claims 1
- 201000002528 pancreatic cancer Diseases 0.000 claims 1
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 230000006289 propionylation Effects 0.000 claims 1
- 238000010515 propionylation reaction Methods 0.000 claims 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510446747.4 | 2015-07-27 | ||
| CN201510446747 | 2015-07-27 | ||
| PCT/CN2016/090800 WO2017016430A1 (zh) | 2015-07-27 | 2016-07-21 | 一种肿瘤抑制肽 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018526987A JP2018526987A (ja) | 2018-09-20 |
| JP2018526987A5 true JP2018526987A5 (enExample) | 2019-08-08 |
| JP6903633B2 JP6903633B2 (ja) | 2021-07-14 |
Family
ID=57883958
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018504942A Active JP6903633B2 (ja) | 2015-07-27 | 2016-07-21 | 腫瘍抑制ペプチド |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US10351613B2 (enExample) |
| EP (1) | EP3330285B1 (enExample) |
| JP (1) | JP6903633B2 (enExample) |
| CN (17) | CN113943363B (enExample) |
| WO (1) | WO2017016430A1 (enExample) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113943363B (zh) * | 2015-07-27 | 2023-11-28 | 上海贺普药业股份有限公司 | 一种肿瘤抑制肽 |
| CN113244370A (zh) * | 2020-02-13 | 2021-08-13 | 珠海市藤栢医药有限公司 | 一种预防和/或治疗神经母细胞瘤的多肽药物及其用途 |
| CN115991739B (zh) * | 2021-12-20 | 2023-10-20 | 珠海市藤栢医药有限公司 | 一种抗肿瘤的多肽及其制备方法和应用 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5854205A (en) * | 1995-10-23 | 1998-12-29 | The Children's Medical Center Corporation | Therapeutic antiangiogenic compositions and methods |
| EP0857210B1 (en) * | 1995-10-23 | 2003-09-03 | The Children's Medical Center Corporation | Therapeutic antiangiogenic compositions and methods |
| US6174861B1 (en) * | 1996-10-22 | 2001-01-16 | The Children's Medical Center Corporation | Methods of inhibiting angiogenesis via increasing in vivo concentrations of endostatin protein |
| US6825167B1 (en) * | 2000-04-03 | 2004-11-30 | Regents Of The University Of Minnesota | Genetic modification of endostatin |
| CN1239516C (zh) * | 2002-02-08 | 2006-02-01 | 中国医学科学院基础医学研究所 | 肿瘤坏死因子相关细胞凋亡诱导配体胞外区突变多肽及其制法与用途 |
| WO2003074551A2 (en) * | 2002-03-01 | 2003-09-12 | The Administrators Of The Tulane Educational Fund | Conjugates of therapeutic or cytotoxic agents and biologically active peptides |
| US20040091465A1 (en) * | 2002-06-26 | 2004-05-13 | Zachary Yim | Therapeutic antiangiogenic compositions and methods |
| US7078485B2 (en) * | 2002-12-05 | 2006-07-18 | Yantai Medgenn Ltd. | N-terminal modified recombinant human endostatin and its production |
| CN1875104A (zh) * | 2003-08-29 | 2006-12-06 | 儿童医学中心公司 | 来自内皮抑素n－末端的抗血管生成肽 |
| US7524811B2 (en) * | 2003-08-29 | 2009-04-28 | Children's Medical Center Corporation | Anti-angiogenic peptides from the N-terminus of endostatin |
| JP2007529410A (ja) * | 2003-08-29 | 2007-10-25 | チルドレンズ メディカル センター コーポレーション | 子宮内膜症を治療又は防止するためのペプチド |
| ES2325344B1 (es) * | 2004-11-02 | 2010-06-09 | Univ Madrid Autonoma | Inhibidores de angiogenesis multifuncionales y multivalentes. |
| CN101062954A (zh) * | 2006-05-16 | 2007-10-31 | 中国人民解放军军事医学科学院野战输血研究所 | 具有抗血管生成作用的融合蛋白及其编码基因与应用 |
| CN100586961C (zh) * | 2006-05-16 | 2010-02-03 | 中国人民解放军军事医学科学院野战输血研究所 | 对肿瘤细胞具有抑制作用的融合蛋白及其编码基因与应用 |
| WO2008125635A1 (en) * | 2007-04-11 | 2008-10-23 | Gene Signal International Sa | Anti-tumor drug, medicament, composition, and use thereof |
| CN101096671A (zh) * | 2007-06-01 | 2008-01-02 | 徐寒梅 | 血管生成抑制剂hm-x及其制备方法和应用 |
| JP2010531666A (ja) * | 2007-06-26 | 2010-09-30 | ユニバーシティ オブ マイアミ | 抗体−エンドスタチン融合タンパク質及びそのバリアント |
| CN102924578A (zh) * | 2011-08-09 | 2013-02-13 | 哈药集团技术中心 | 抗肿瘤多肽及其制备方法和抗肿瘤应用 |
| EP2561888A1 (en) * | 2011-08-23 | 2013-02-27 | Deutsches Krebsforschungszentrum | Protein comprising NC-1 for treating angiogenesis-related diseases |
| CN113943363B (zh) * | 2015-07-27 | 2023-11-28 | 上海贺普药业股份有限公司 | 一种肿瘤抑制肽 |
-
2016
- 2016-07-21 CN CN202111155175.6A patent/CN113943363B/zh active Active
- 2016-07-21 WO PCT/CN2016/090800 patent/WO2017016430A1/zh not_active Ceased
- 2016-07-21 CN CN201680044076.1A patent/CN107922475B/zh active Active
- 2016-07-21 CN CN202111155262.1A patent/CN113943365B/zh active Active
- 2016-07-21 CN CN202111152258.XA patent/CN113717275B/zh active Active
- 2016-07-21 CN CN202111152272.XA patent/CN113717278B/zh active Active
- 2016-07-21 CN CN202111151032.8A patent/CN113717274B/zh active Active
- 2016-07-21 CN CN202111152259.4A patent/CN113717276B/zh active Active
- 2016-07-21 CN CN202111155543.7A patent/CN113980119B/zh active Active
- 2016-07-21 CN CN202111153255.8A patent/CN115433267A/zh active Pending
- 2016-07-21 CN CN202111152378.XA patent/CN113912705B/zh active Active
- 2016-07-21 CN CN202111153309.0A patent/CN115433269B/zh active Active
- 2016-07-21 US US15/746,978 patent/US10351613B2/en active Active
- 2016-07-21 EP EP16829796.8A patent/EP3330285B1/en active Active
- 2016-07-21 CN CN202111155244.3A patent/CN114031683B/zh active Active
- 2016-07-21 CN CN202111153273.6A patent/CN115433268B/zh active Active
- 2016-07-21 JP JP2018504942A patent/JP6903633B2/ja active Active
- 2016-07-21 CN CN202111152268.3A patent/CN113717277B/zh active Active
- 2016-07-21 CN CN202111153334.9A patent/CN115433270B/zh active Active
- 2016-07-21 CN CN202111155210.4A patent/CN113943364B/zh active Active
- 2016-07-21 CN CN202111155546.0A patent/CN113980120B/zh active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112021022315A2 (pt) | Ligantes de peptídeo bicíclicos específicos para ox40 | |
| JP2018509935A5 (enExample) | ||
| JP2015519313A5 (enExample) | ||
| JP2019525753A5 (enExample) | ||
| JP2019527706A5 (enExample) | ||
| JP2011511753A5 (enExample) | ||
| JP2018509936A5 (enExample) | ||
| JP2016501829A5 (enExample) | ||
| JP2016521257A5 (enExample) | ||
| IL308807B2 (en) | Combination therapy for treating cancer | |
| IN2014KN01713A (enExample) | ||
| IN2014KN01714A (enExample) | ||
| JP2017502081A5 (enExample) | ||
| JP2016516407A5 (enExample) | ||
| JP2018526987A5 (enExample) | ||
| RU2017119773A (ru) | Пептидные антагонисты пептидных гормонов из семейства кальцитонина (cgrp) и их применение | |
| CN106232616A (zh) | 两亲性合成抗菌肽、其药物组合物及其用途 | |
| JP2019511550A5 (enExample) | ||
| JP2012529293A5 (enExample) | ||
| JP2018500385A5 (enExample) | ||
| NZ708990A (en) | Method for activating helper t cell | |
| JP2017529870A5 (enExample) | ||
| JP2019534884A5 (enExample) | ||
| JP2017505772A5 (enExample) | ||
| JP2012514466A5 (enExample) |